Skip Content
You are currently on the new version of our website. Access the old version .
MDPIMDPI
IJMSInternational Journal of Molecular Sciences
Download PDF
  • Editorial
  • Open Access

8 January 2020

Revisiting the Pharmacological Value of Glucagon: An Editorial for the Special Issue “The Biology and Pharmacology of Glucagon”

and
1
Institute for Diabetes and Obesity, Helmholtz Diabetes Center, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), 85764 Neuherberg, Germany
2
German Center for Diabetes Research (DZD), 85764 Neuherberg, Germany
3
Department of Pharmacology and Experimental Therapy, Institute of Experimental and Clinical Pharmacology and Toxicology, Eberhard Karls University Hospitals and Clinics, 72076 Tübingen, Germany
4
Department of Medicine-Endocrinology and Diabetes and Metabolism, Comprehensive Diabetes Center, University of Alabama at Birmingham, Birmingham, AL 35899, USA
Int. J. Mol. Sci.2020, 21(2), 383;https://doi.org/10.3390/ijms21020383
This article belongs to the Special Issue The Biology and Pharmacology of Glucagon
Version Notes
Order Reprints
In 1921, a Canadian research team led by Frederick Banting and John Macleod succeeded in the isolation of insulin from pancreatic homogenate [1] and thereby turned juvenile-onset (type 1) diabetes from a fatal to a manageable disease. Overshadowed by the monumental importance of this discovery was the observation that their insulin preparation first notably increased blood glucose before the much-heralded drop in glycemia was observed [2]. In 1923, the same year in which Banting and Macleod were awarded the Nobel Prize in Medicine for their discovery, Charles Kimball and John Murlin identified this hyperglycemic factor and named it glucagon [3]. Secreted from the pancreatic α-cells in negative correlation to blood glucose, glucagon acts on the liver to enhance de novo glucose production and to stimulate the breakdown of glycogen [4,5,6,7,8,9,10]. Ever since, glucagon is largely recognized for its ability to oppose the hyperglycemic effects of insulin with therapeutic value largely restricted to treat severe hypoglycemia. This negative image of glucagon is further spurred by the demonstration that the inadequate postprandial suppression of glucagon secretion can contribute to hyperglycemia and the development of type 2 diabetes (T2D) [11,12,13,14,15], whereas the blocking of glucagon action improves glucose metabolism in rodents, dogs, monkeys, and humans (as reviewed in [16]). Stigmatized for being largely of diabetogenic nature, glucagon is a pleiotropic hormone with metabolic action that goes far beyond the regulation of blood glucose.
Emerging evidence suggests that beyond its counterregulatory role in glucose homeostasis, glucagon regulates a range of actions including lipolysis, ketogenesis, fatty acid oxidation, satiety, food intake, thermogenesis, energy expenditure (EE), and bile acid metabolism. These glucagon-mediated improvements in lipid and energy metabolism may be quite desirable in patients with the metabolic syndrome. However, the exact mechanism(s) by which glucagon elicits its beneficial metabolic responses, or more importantly, how they can be balanced against glucagon-stimulated diabetogenesis, have yet to be elucidated.
However, in 2009, a novel peptide was characterized by Day et al. that combined the antidiabetic and anorexic properties of GLP-1 with the thermogenic and lipolytic effects of glucagon (GCG) in a single molecule based on the GCG backbone [17]. Intriguingly, the antidiabetic actions of GLP-1R agonism are enhanced by the catabolic and hypolipidemic properties of glucagon receptor (GCGR) agonism [17]. Importantly, this GLP-1R/GCGR mixed agonist lacked the classic acute diabetogenic effects often attributed to GCGR activity [17]. In the same month as this initial report, a similar molecule (i.e., GLP-1/GCGR single-molecule co-agonist) was reported by Pocai et al. [18]. This version was based on the oxyntomodulin sequence and contained full activity at both GLP-1 and GCG receptors and stimulated similar beneficial effects in diet-induced obese (DIO) mice as the “Day” molecule. Together, these two preclinical studies set the stage for an anti-diabetic therapeutic that included GCGR, a thought that was antithetical prior to this evidence. Following on the heels of these preclinical rodent studies, it was observed that co-administration of GCG and GLP-1 in humans stimulated energy expenditure while reducing GCGR-associated hyperglycemia [19], thus confirming the translational importance of this strategy. With the success of these early studies, it is of no surprise that another GLP-1/glucagon co-agonist, MEDI0382, displayed potent effects on weight loss, hepatic fat content, and glucose metabolism in DIO mice and cynomolgus monkeys [20]. This specific compound has since passed safety and tolerability endpoints in phase I trials [21], as well as displaying impressive metabolic benefits in phase IIa. MEDI0382 specifically reduced postprandial blood glucose, body weight, and hepatic fat content in patients with T2D [22]. More recent findings have established the value of adding the glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism to that of GLP-1/GCGR [23]. Together, these findings argue for a reevaluation of glucagon as a therapeutic target, a topic highlighted in this Special Issue.
This Special Issue, “Glucagon”, contains ten review articles covering a wide range of glucagon actions, including the metabolic effects of glucagon, methodology in glucagon research, glucagon receptor signaling, and potential therapeutic avenues for glucagon (Table 1).
Table 1. Overview of “The Biology and Pharmacology of Glucagon”.
Several articles in this issue discussed themes on metabolic action regulated by glucagon receptor signaling. Al-Massadi and colleagues highlight the anti-obesity effects of glucagon via its stimulation of energy expenditure and lipid metabolism while concomitantly suppressing food intake [25]. González-García et al. extend upon the topic of energy expenditure to discuss the regulation of thermogenesis following GLP-1 or GCGR agonism [26]. Of note, this review delves into potential mechanisms of brown versus beige adipose activation by these highly related hormones in the regulation of thermogenesis. Kleinert and colleagues similarly address mechanisms underlying glucagon regulation of systemic metabolism, emphasizing the role of thermogenesis in this action and highlighting important differences of glucagon’s thermogenic action depending on whether glucagon is given acutely or chronically [27]. In the final review of this topic, Zhang et al. discuss critical intracellular targets of GCGR signaling in liver [28]. This review provides convincing arguments for acetylation of energy-sensing factors in response to GCGR agonism as the intracellular mechanism(s) for glucagon-stimulated hepatic action. Similar reviews follow with an emphasis on GCGR signaling. Reviews by Al-Zamel et al. as well as Mathiesen and colleagues address regulation of glucagon production/secretion following activation of the canonical incretin axis (i.e., GIP- and GLP1-R) [29,30]. These intriguing reviews highlight the role of glucagon in an emerging class of anti-diabetic and anti-obesity therapeutics. Although described almost 100 years ago, the accurate and precise measurement of glucagon has been a constant challenge to the field. Within this issue is an important piece from Holst and Wewer Albrechtsen regarding methodologies and recommendations for measuring glucagon in circulation [31]. The two remaining reviews of this issue include detailed analyses of insulin resistance and α-cell dysfunction by Honzawa et al. [32] as well as exciting new therapeutic options for glucagon rescue of hypoglycemia via intranasal delivery by Pontiroli and Tagliabue [33].
Overall, the collection of these ten reviews provide a historical context to the field of glucagon biology. More importantly, these articles highlight the current focus of the field, and offer insight into novel directions for work on this long-known hormone.

Acknowledgments

The handling editors of this Special Issue thank all contributing authors for their participation and efforts.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Banting, F.G.; Best, C.H.; Collip, J.B.; Campbell, W.R.; Fletcher, A.A. Pancreatic Extracts in the Treatment of Diabetes Mellitus. Can. Med. Assoc. J. 1922, 12, 141–146. [Google Scholar] [PubMed]
  2. Fisher, N.F. Preparation of insulin. Am. J. Physiol. 1923, 67, 57. [Google Scholar] [CrossRef]
  3. Kimball, C.; Murlin, J. Aqueous extracts of pancreas III. Some precipitation reactions of insulin. J. Biol. Chem. 1923, 58, 337–348. [Google Scholar]
  4. Bürger, M.; Brandt, W. Über das Glukagon (die hyperglykämisierende Substanz der Pankreas). Z. Ges. Exp. Med. 1935, 96, 375. [Google Scholar] [CrossRef]
  5. Bürger, M.; Kramer, H. Über den hepatischen Angriffspunkt des Insulins. Die primäre Paradoxe Insulinhyperglykämie. Z. Ges. Exp. Med. 1929, 65, 487. [Google Scholar] [CrossRef]
  6. Bürger, M.; Kramer, H. Primäre Hyperglykämie und Glykogenveränderung der Leber als Folge intraportaler Insulininjektion nach Untersuchungen am Hund. Z. Ges. Exp. Med. 1929, 67, 441. [Google Scholar] [CrossRef]
  7. Exton, J.H.; Park, C.R. Control of gluconeogenesis in liver. II. Effects of glucagon, catecholamines, and adenosine 3’,5’-monophosphate on gluconeogenesis in the perfused rat liver. J. Biol Chem. 1968, 243, 4189–4196. [Google Scholar]
  8. Garcia, A.; Williamson, J.R.; Cahill, G.F., Jr. Studies on the perfused rat liver. II. Effect of glucagon on gluconeogenesis. Diabetes 1966, 15, 188–193. [Google Scholar] [CrossRef]
  9. Struck, E.; Ashmore, J.; Wieland, O. Stimulation of gluconeogenesis by long chain fatty acids and glucagon. Biochem. Z. 1965, 343, 107–110. [Google Scholar]
  10. Ui, M.; Claus, T.H.; Exton, J.H.; Park, C.R. Studies on the mechanism of action of glucagon on gluconeogenesis. J. Biol. Chem. 1973, 248, 5344–5349. [Google Scholar]
  11. Gerich, J.E.; Langlois, M.; Noacco, C.; Lorenzi, M.; Karam, J.H.; Korsham, P.H. Comparison of the suppressive effects of elevated plasma glucose and free fatty acid levels on glucagon secretion in normal and insulin-dependent diabetic subjects. Evidence for selective alpha-cell insensitivity to glucose in diabetes mellitus. J. Clin. Investig. 1976, 58, 320–325. [Google Scholar] [CrossRef]
  12. Gerich, J.E.; Lorenzi, M.; Schneider, V.; Karam, J.H.; Rivier, J.; Guillemin, R.; Forsham, P.H. Effects of somatostatin on plasma glucose and glucagon levels in human diabetes mellitus. Pathophysiologic and therapeutic implications. N. Engl. J. Med. 1974, 291, 544–547. [Google Scholar] [CrossRef]
  13. Dobbs, R.; Sakurai, H.; Sasaki, H.; Faloona, G.; Valverde, I.; Baetens, D.; Orci, L.; Unger, R. Glucagon: Role in the hyperglycemia of diabetes mellitus. Science 1975, 187, 544–547. [Google Scholar] [CrossRef]
  14. Muller, W.A.; Faloona, G.R.; Aguilar-Parada, E.; Unger, R.H. Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N. Engl. J. Med. 1970, 283, 109–115. [Google Scholar] [CrossRef]
  15. Unger, R.H.; Aguilar-Parada, E.; Muller, W.A.; Eisentraut, A.M. Studies of pancreatic alpha cell function in normal and diabetic subjects. J. Clin. Investig. 1970, 49, 837–848. [Google Scholar] [CrossRef]
  16. Muller, T.D.; Finan, B.; Clemmensen, C.; DiMarchi, R.D.; Tschop, M.H. The New Biology and Pharmacology of Glucagon. Physiol. Rev. 2017, 97, 721–766. [Google Scholar] [CrossRef]
  17. Day, J.W.; Ottaway, N.; Patterson, J.T.; Gelfanov, V.; Smiley, D.; Gidda, J.; Findeisen, H.; Bruemmer, D.; Drucker, D.J.; Chaudhary, N.; et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat. Chem. Biol. 2009, 5, 749–757. [Google Scholar] [CrossRef]
  18. Pocai, A.; Carrington, P.E.; Adams, J.R.; Wright, M.; Eiermann, G.; Zhu, L.; Du, X. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes 2009, 58, 2258–2266. [Google Scholar] [CrossRef]
  19. Tan, T.M.; Field, B.C.; McCullough, K.A.; Troke, R.C.; Chambers, E.S.; Salem, V.; Gonzalez Maffe, J.; Baynes, K.C.; De Silva, A.; Viardot, A.; et al. Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes 2013, 62, 1131–1138. [Google Scholar] [CrossRef]
  20. Henderson, S.J.; Konkar, A.; Hornigold, D.C.; Trevaskis, J.L.; Jackson, R.; Fritsch Fredin, M.; Jansson-Löfmark, R.; Naylor, J.; Rossi, A.; Bednarek, M.A.; et al. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates. Diabetes Obes. Metab. 2016, 18, 1176–1190. [Google Scholar] [CrossRef]
  21. Ambery, P.D.; Klammt, S.; Posch, M.G.; Petrone, M.; Pu, W.; Rondinone, C.; Jermutus, L.; Hirshberg, B. MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study. Br. J. Clin. Pharmacol. 2018, 84, 2325–2335. [Google Scholar] [CrossRef]
  22. Ambery, P.; Parker, V.E.; Stumvoll, M.; Posch, M.G.; Heise, T.; Plum-Moerschel, L.; Tsai, L.F.; Robertson, D.; Jain, M.; Petrone, M.; et al. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: A randomised, controlled, double-blind, ascending dose and phase 2a study. Lancet 2018, 391, 2607–2618. [Google Scholar] [CrossRef]
  23. Finan, B.; Yang, B.; Ottaway, N.; Smiley, D.L.; Ma, T.; Clemmensen, C.; Chabenne, J.; Zhang, L.; Habegger, K.M.; Fischer, K.; et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat. Med. 2015, 21, 27–36. [Google Scholar] [CrossRef] [PubMed]
  24. Janah, L.; Kjeldsen, S.; Galsgaard, K.D.; Winther-Sørensen, M.; Stojanovska, E.; Pedersen, J.; Knop, F.K.; Holst, J.J.; Wewer Albrechtsen, N.J. Glucagon Receptor Signaling and Glucagon Resistance. Int. J. Mol. Sci. 2019, 20, 3314. [Google Scholar] [CrossRef]
  25. Al-Massadi, O.; Ferno, J.; Dieguez, C.; Nogueiras, R.; Quinones, M. Glucagon Control on Food Intake and Energy Balance. Int. J. Mol. Sci. 2019, 20, 3905. [Google Scholar] [CrossRef]
  26. Gonzalez-Garcia, I.; Milbank, E.; Dieguez, C.; Lopez, M.; Contreras, C. Glucagon, GLP-1 and Thermogenesis. Int. J. Mol. Sci. 2019, 20, 3445. [Google Scholar] [CrossRef]
  27. Kleinert, M.; Sachs, S.; Habegger, K.M.; Hofmann, S.M.; Muller, T.D. Glucagon Regulation of Energy Expenditure. Int. J. Mol. Sci. 2019, 20, 5407. [Google Scholar] [CrossRef]
  28. Zhang, L.; Yao, W.; Xia, J.; Wang, T.; Huang, F. Glucagon-Induced Acetylation of Energy-Sensing Factors in Control of Hepatic Metabolism. Int. J. Mol. Sci. 2019, 20, 1885. [Google Scholar] [CrossRef]
  29. Al-Zamel, N.; Al-Sabah, S.; Luqmani, Y.; Adi, L.; Chacko, S.; Schneider, T.D.; Krasel, C. A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor. Int. J. Mol. Sci. 2019, 20, 3532. [Google Scholar] [CrossRef]
  30. Mathiesen, D.S.; Bagger, J.I.; Bergmann, N.C.; Lund, A.; Christensen, M.B.; Vilsbøll, T.; Knop, F.K. The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion-A Review. Int. J. Mol. Sci. 2019, 20, 4092. [Google Scholar] [CrossRef]
  31. Holst, J.J.; Wewer Albrechtsen, N.J. Methods and Guidelines for Measurement of Glucagon in Plasma. Int. J. Mol. Sci. 2019, 20, 5416. [Google Scholar] [CrossRef]
  32. Honzawa, N.; Fujimoto, K.; Kitamura, T. Cell Autonomous Dysfunction and Insulin Resistance in Pancreatic alpha Cells. Int. J. Mol. Sci. 2019, 20, 3699. [Google Scholar] [CrossRef] [PubMed]
  33. Pontiroli, A.E.; Tagliabue, E. Therapeutic Use of Intranasal Glucagon: Resolution of Hypoglycemia. Int. J. Mol. Sci. 2019, 20, 3646. [Google Scholar] [CrossRef] [PubMed]

Article Metrics

Citations

Article Access Statistics

Journal Statistics
Multiple requests from the same IP address are counted as one view.
Download PDF
New Insights into the Biological and Pharmaceutical Properties of Royal Jelly
Previous
In Vivo Metabolic Response upon Exposure to Gold Nanorod Core/Silver Shell Nanostructures: Modulation of Inflammation and Upregulation of Dopamine
Next